[1]张世玺,徐立然,周文亮.经导管肝动脉化疗栓塞术联合射频消融术及药物治疗原发性肝癌35例临床观察[J].甘肃中医药大学学报,2019,36(05):54-57.[doi:10.16841/j.issn1003-8450.2019.05.12]
 ZHANG Shixi,XU Liran,ZHOU Wenliang.Clinical observation on 35 cases of transcatheter arterial chemoembolization combined with radiofrequency ablation and medication in the treatment of primary hepatocarcinoma[J].Journal of Gansu University of Chinese Medicine,2019,36(05):54-57.[doi:10.16841/j.issn1003-8450.2019.05.12]
点击复制

经导管肝动脉化疗栓塞术联合射频消融术及药物治疗原发性肝癌35例临床观察()
分享到:

《甘肃中医药大学学报》[ISSN:1003-8450/CN:62-1062/R]

卷:
36卷
期数:
2019年05期
页码:
54-57
栏目:
临床研究与报道
出版日期:
2019-10-25

文章信息/Info

Title:
Clinical observation on 35 cases of transcatheter arterial chemoembolization combined with radiofrequency ablation and medication in the treatment of primary hepatocarcinoma
作者:
张世玺 徐立然 周文亮
商丘市立医院(商丘市第一人民医院分院)感染科, 河南 商丘 476100
Author(s):
ZHANG Shixi XU Liran ZHOU Wenliang
Infection Section, Shangqiu Municipal Hospital(Shangqiu the First People’s Hospital Branch), Shangqiu, Henan, 476100, China
关键词:
原发性肝癌经导管肝动脉化疗栓塞术射频消融术微创索拉非尼华蟾素胶囊临床观察
Keywords:
primary hepatocarcinomatranscatheter arterial chemoembolization(TACE)radiofrequency ablation(RFA)microinvasionsorafenibHuachansu Jiaonangclinical observation
分类号:
R735.7
DOI:
10.16841/j.issn1003-8450.2019.05.12
摘要:
目的 观察经导管肝动脉化疗栓塞术(TACE)联合射频消融术(RFA)及药物治疗原发性肝癌的临床疗效。方法 将50例原发性肝癌患者随机分为微创组15例和联合组35例。微创组采用TACE联合RFA治疗,联合组在微创组治疗方法的基础上给予药物治疗。2年后比较2组的临床疗效、2年生存率及治疗期间的不良反应发生情况(包括皮疹,腹泻,恶心、呕吐,手掌或足底发红,血压升高等)。结果 微创组总有效率为40.0%,联合组为62.8%,2组比较差异有统计学意义(P<0.05);微创组出现不良反应较少,联合组出现皮疹10例,腹泻12例,恶心、呕吐13例,手掌或足底发红5例,血压升高6例,与微创组比较差异均有统计学意义(P<0.05);微创组2年生存率为26.7%,联合组为42.8%,2组比较差异有统计学意义(P<0.05)。结论 TACE联合RFA及药物治疗原发性肝癌临床疗效显著,可明显延长患者的生存年限,且不良反应可控,值得临床推广应用。
Abstract:
Objective To observe the clinical efficacy of transcatheter arterial chemoembolization(TACE) combined with radiofrequency ablation(RFA) and medication in the treatment of primary hepatocarcinoma. Methods Fifty cases of primary hepatocarcinoma were divided into microinvasion group with 15 cases and combined group with 35 cases. The microinvasion group was given TACE combined with RFA treatment,on this basis,the combined group was given medication. After 2 years,the clinical efficacy,the 2 year survival rate and the adverse reactions occurred during the treatment(including rashes,diarrhea,nausea,vomiting,redness of the palms or plantae,blood pressure elevation,etc.)of the 2 groups were compared. Results The total effective rate of the microinvasion group was 40.0%,that of the combined group was 62.8%,and the difference between the 2 groups was statistically significant(P<0.05). There were fewer adverse reactions in the microinvasion group,10 cases of rash,12 cases of diarrhea,13 cases of nausea and vomiting,5 cases of red palms or plantae,and 6 cases of blood pressure elevation in the combined group,all of which were statistically significant compared with the microinvasion group(P<0.05).The 2 year survival rate was 26.7% in the microinvasion group and 42.8% in the combined group,and the difference between the 2 groups was statistically significant(P<0.05). Conclusion TACE combined with RFA and medication in the treatment of primary hepatocarcinoma has marked clinical efficacy,which can significantly prolong the life span of the patients with controllable adverse reactions. It deserves clinical promotion and application.

参考文献/References:

[1] Jemal A,Bray F,Center M M,et al.Global cancer statistics[J].C A cancer J Clin,2011,61(2):69-90.
[2] LI K W,LI X,WEN T F,et al.The effect of postoperative TACE on prognosis of HCC:an update[J].Hepatogastroenterology,2013,60(122):248-251.
[3] 张世玺.B超联合CT下行射频消融术治疗原发性肝癌的临床效果观察[J].中国综合临床,2014,30(7):681-683.
[4] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].中华肝脏病杂志,2009(17):403-410.
[5] Lencioni R,Llovet J M.Modified recist(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.
[6] 王长青,雷久士.中医药治疗原发性肝癌的临床研究[J].中医药导报,2010(16):80-82.
[7] Choi S H,Choi G H,Kim S U,et al.Role of surgical resection for multiple hepatocellular carcinomas[J].World J Gastroenterol,2013,19(3):366-374.
[8] LI S H,GUO Z X,XIAO C Z,et al.Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection[J].Asian Pac J Cancer Prev,2013,14(8):4759-4763.
[9] 邓丽芬,王艳红,贾庆安,等.索拉非尼联合5-氟尿嘧啶对人肝癌细胞株MHCCLM3增殖的抑制作用[J].中华肝脏病杂志,2013,21(11):845-849.

相似文献/References:

[1]王彤.中药艾迪联合肝介入化疗治疗老年肝癌疗效观察[J].甘肃中医药大学学报,2004,(03):19.

备注/Memo

备注/Memo:
收稿日期:2018-11-13。
基金项目:国家十二五科技重大专项资金资助项目(2013ZX10005001)。
作者简介:张世玺(1980-),男,副主任医师,医学硕士,主要从事肝癌的微创和内科治疗。
更新日期/Last Update: 1900-01-01